JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy.
A new immunotherapy designed to avoid the dangerous side effects of older IL-2 drugs shows strong tumor control in early models without systemic toxicity.
By combining weak IL-2/15Rβγ-agonistic nanobodies with anti-PD-1 IgG, JMB2403 achieves conditional STAT5 activation only in PD-1-high activated T cells, avoiding the systemic IL-2 toxicities (vascular leak, pulmonary edema) that have hampered prior immunocytokine approaches. In A375 and NCI-H292 xenograft models JMB2403 outperformed parental anti-PD-1, and in cynomolgus monkeys it produced dose-dependent CD8+ T cell expansion without toxicity, establishing a promising IND-enabling dataset.
What the study was
- Study design
- preclinical_in_vivo
- Category
- novel_therapeutics
- Maturity
- Exploratory
- Journal
- MAbs
Why it surfaced
First tri-specific antibody of its class; elegantly solves the IL-2 toxicity vs. efficacy trade-off for solid tumors—a major unmet need in immuno-oncology; non-human primate safety data de-risk clinical translation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.